王红艳 研究员
硕士招生类型：
硕士招生专业：
博士招生类型：学术型
博士招生专业：临床医学（生物医学方向）
所在院系：附属第十人民医院
联系方式：hongyanwang@sibcb.ac.cn
课题组链接：
研究方向
主要任职
科研业绩

巨噬细胞和T细胞与炎症相关疾病
Functionof macrophage and T cells in inflammatory diseases

任JBC编委Immunology编委、中国细胞生物学学报编委
中国免疫学会基础免疫分会委员、整合医学上海分会委员、中国抗癌协会肿瘤微环境专业青年委员会副主任、中国生物医学工程学会委员。

Theeditor of Journal of Biological Chemistry, Immunology, Chinese Journal of cellbiology, Frontier Journal of Immunology.
Memberof Basic research community of Chines society of Immunology, Shanghai communityof Integrated medicine, Chinese Biomedical Engineering Society.


创新性发现VEGFR-3、STK4等一系列信号分子调控巨噬细胞TLR通路，成为诊断或阻断败血症、炎症相关肝癌的新靶点（Immunity，JCI， Cell Rep， JBC）；发现T细胞中的新型信号分子LRCH1抑制细胞迁移的新机制（JEM），并阐述ADAP调控CD8+T细胞抗肿瘤或抗病毒感染的新功能（EMBO MM，PLoS Pathog，Retrovirology）。
在Immunity、Nat Immunol、Trends Cell Biol等发表30余篇文章。近5年以通讯（或共同通讯）作者发表13篇论文，包括Immunity（封面故事）、Nature Microbiology、J Clin Invest、J Exp Med、Cell Res（封面故事）、EMBO Mol Med、PLoS Pathogens、Cell Rep等。获得授权发明专利3项。
A series of key signal molecules such as VEGFR-3, STK4,Hrd1 have been identified, which are new targets to inhibit macrophage TLRpathway and block excessive inflammation (Immunity, JCI, Cell Rep, JBC)-relatedhepatocellular carcinoma or sepsis. We also identified the new effector LRCH1for inhibiting cell migration and preventing T cell-mediated EAE (JEM). Wereported the new function of ADAP in the regulation of CD8+T cells against tumoror virus infection (EMBO MM, PLoS Pathog, Retrovirology).
Publishedmore than 30 articles in Immunity、NatImmunol、Trends Cell Biol etc. Inthe past five years, Prof Wang has published 13 papers as the correspondingauthor, including Immunity (cover story), J Clin Invest, J Exp Med, Cell Res(cover story), EMBO Mol Med, PLoS Pathogens, Cell Rep, etc. Three patents havebeen granted.